Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RLMD Relmada Therapeutics, Inc.

Closed Good Friday 04-17 16:00:00 EDT

0.2898

-0.0022

-0.75%

盘后0.2870

-0.0028-0.97%

18:57 EDT

High0.3156	Low0.2830	Vol111.99K
Open0.2903	D1 Closing0.2920	Amplitude11.16%
Mkt Cap9.62M	Tradable Cap8.86M	Total Shares33.19M
T/O33.30K	T/O Rate0.37%	Tradable Shares30.57M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"RLMD","market":"US","secType":"STK","nameCN":"Relmada Therapeutics, Inc.","latestPrice":0.2898,"timestamp":1744920000000,"preClose":0.292,"halted":0,"volume":111992,"hourTrading":{"tag":"盘后","latestPrice":0.287,"preClose":0.2898,"latestTime":"18:57 EDT","volume":17673,"amount":5292.0933,"timestamp":1744930667597},"delay":0,"floatShares":30568066,"shares":33191622,"eps":-2.651505,"marketStatus":"Closed Good Friday","change":-0.0022,"latestTime":"04-17 16:00:00 EDT","open":0.2903,"high":0.3156,"low":0.283,"amount":33304.516936,"amplitude":0.111644,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-2.651505,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":0.292,"preHourTrading":{"tag":"盘前","latestPrice":0.296,"preClose":0.292,"latestTime":"09:24 EDT","volume":804,"amount":235.1146044,"timestamp":1744896286642},"postHourTrading":{"tag":"盘后","latestPrice":0.287,"preClose":0.2898,"latestTime":"18:57 EDT","volume":17673,"amount":5292.0933,"timestamp":1744930667597},"volumeRatio":0.4871482139154457,"impliedVol":1.2528,"impliedVolPercentile":0.3506},"requestUrl":"/m/hq/s/RLMD","defaultTab":"news","newsList":[{"id":"2527159483","title":"Relmada Therapeutics To Present NDV-01 Data at AUA2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2527159483","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2527159483?lang=en_us&edition=full_marsco","pubTime":"2025-04-14 19:30","pubTimestamp":1744630200,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., April 14, 2025  -- Relmada Therapeutics, Inc. , a clinical-stage biotechnology company, today announced the presentation of an abstract at the American Urology Association , taking place from April 26-29th in Las Vegas.Prospective Open Label Study to Evaluate the Safety and Efficacy of Safety and Efficacy of intravesical sustained release Gemcitabine Docetaxel combination  in High Risk NMIBC: P2 on Apr 25. About NDV-01NDV-01 is an investigational, innovative sustained-release formulation of two complementary, well-established, chemotherapy agents, gemcitabine and docetaxel . It is designed for intravesical dosing and intended to be an in-office ready-to-use therapy that is administered rapidly and requires no anesthesia or new or dedicated equipment to employ. NDV-01 forms a spherical soft matrix within the bladder that sequesters drug and releases it as the matrix gradually dissolves.NDV-01 is protected by several patents that go out to 2038.The U.S. NMIBC market i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-present-ndv-01-113000967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4007","RLMD","BK4139","LENZ"],"gpt_icon":0},{"id":"2522679522","title":"Q4 2024 Relmada Therapeutics Inc Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2522679522","media":"Thomson Reuters StreetEvents","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522679522?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 19:05","pubTimestamp":1743159928,"startTime":"0","endTime":"0","summary":"Brian Ritchie; Managing Director, LifeSci Advisors, LLC; Relmada Therapeutics Inc. Sergio Traversa; Chief Executive Officer, Director; Relmada Therapeutics Inc. Maged Shenouda; Chief Financial Officer; Relmada Therapeutics Inc. Greetings and welcome to the Relmada Therapeutics Incorporated quarter four 2024 financial results call.It is now my pleasure to introduce Brian Ritchie.Thank you. Brian, you may be good.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/q4-2024-relmada-therapeutics-inc-110528479.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD","LENZ"],"gpt_icon":0},{"id":"2522197895","title":"Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ...","url":"https://stock-news.laohu8.com/highlight/detail?id=2522197895","media":"GuruFocus.com","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522197895?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 15:03","pubTimestamp":1743145411,"startTime":"0","endTime":"0","summary":"Cash Equivalents and Short-term Investments: $44.9 million as of December 31, 2024, compared to $96.3 million as of December 31, 2023.Cash Used in Operations: $8.8 million for Q4 2024, compared to $10.2 million for Q4 2023.Research and Development Expense: $11 million for Q4 2024, compared to $14.7 million for Q4 2023.General and Administrative Expense: $8.1 million for Q4 2024, compared to $12.1 million for Q4 2023.Net Loss: $18.6 million or $0.62 per share for Q4 2024, compared to $25.1 million or $0.84 per share for Q4 2023.GuruFocus has detected 2 Warning Signs with RLMD.Relmada Therapeutics Inc  has successfully acquired rights to two promising candidates, NDVA1 for non-muscle invasive bladder cancer and Sopranoon for compulsion-related disorders, enhancing their product pipeline.Q: Can you explain the process involved in the acquisition deals, particularly for NDVO1, and why these companies chose Relmada over other bidders?A: Sergio Traversa, CEO, explained that the acquisition o","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-inc-rlmd-q4-070331586.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RLMD"],"gpt_icon":0},{"id":"2522534133","title":"Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2522534133","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522534133?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:40","pubTimestamp":1743108002,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc reports results for the quarter ended December 31 - Earnings SummaryRelmada Therapeutics Inc RLMD.OQ reported a quarterly adjusted loss of 62 cents per share for the quarter e","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nL5N3QA247:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0},{"id":"2522539163","title":"BRIEF-Relmada Therapeutics Q4 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539163","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539163?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105946,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Q4 EPS USD -0.62\n\n\nMar 27 (Reuters) - Relmada Therapeutics Q4 net income USD -18.6 million.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0},{"id":"2522853996","title":"Relmada Therapeutics Q4 EPS USD -0.62","url":"https://stock-news.laohu8.com/highlight/detail?id=2522853996","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522853996?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2522539983","title":"Relmada Therapeutics: Expect Topline Phase 2 Data for Ndv-01 for High-Grade Non-Muscle Invasive Bladder Cancer (Hg-Nmibc)","url":"https://stock-news.laohu8.com/highlight/detail?id=2522539983","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522539983?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105901,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250327:nPLX41B5DF:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2522653140","title":"Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2522653140","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522653140?lang=en_us&edition=full_marsco","pubTime":"2025-03-28 04:05","pubTimestamp":1743105900,"startTime":"0","endTime":"0","summary":"Expect Topline Phase 2 data for NDV-01 for high-grade non-muscle invasive bladder cancer, to be presented at AUA 2025 in April. Advancing novel neurosteroid, sepranolone, towards Phase 2b study in Tourette syndrome with plans for evaluation in other compulsion-related disorders, including Prader-Willi Syndrome. Cash balance of $44.8 million as of December 31 2024. Management hosting conference call and webcast today at 4:30 PM ET. “An important dimension of our strategic options exploration has been the development of a portfolio of programs with near-term value drivers that can address under-served markets. While we maintain deep expertise in diseases of the central nervous system, as we evaluate strategic opportunities, the broad drug development expertise of our Team provides flexibility to be opportunistic,” commented Maged Shenouda, CFO of Relmada. “With a $44.8 million cash balance, as of December 31, 2024, and clean balance sheet, we begin the year with solid financial strength.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/relmada-therapeutics-reports-fourth-quarter-200500181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ALLO","IE00B1B80R65.USD","TS","BK4532","BK4179","BK4563","PWS","LENZ","RLMD","BK4505","CDC","PAM","BK4007","BK4081","BK4139"],"gpt_icon":0},{"id":"2522329609","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2522329609","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522329609?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 18:00","pubTimestamp":1743069600,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·INmune Bio Inc.                                 4Q      (.55)  4:05 PM. ·TD SYNNEX Corp                                   1Q      2.91   8:05 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLRX","PVLA","SDST","CELC","KYTX","PENG","CLSD","SKYH","RANI","FBIO","ADCT","PRGS","LULU","RLMD","FEMY","BRZE","TSAT","AFMD","WGO","ANGO","ATAI","SLRN","CALC","GWH","FTCI","LNZA","MDAI","BHST","EDAP","SPWH","UNCY","IKT","INMB","FC","BW","NCNO","DARE","PVH","WBA","SGML","NUTX","GEVO","GOVX","INR","CRDL","NNOX","TLSI","WKSP","BCAB","REKR"],"gpt_icon":0},{"id":"2522355038","title":"BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522355038","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522355038?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:05","pubTimestamp":1743023102,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC FilingMarch 26  - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS INC -ON MARCH 24, ENTERS EXCLUSIVE LICENSE AGREEMENT WITH TRIGONE PHARMA - SEC FILINGRELMADA THERAPEUTICS INC - TO PAY $3.5 MILLION INITIAL LICENSE FEE TO TRIGONE - SEC FILINGSource text: [ID:n0001013762-25-002786]Further company coverage: RLMD.O ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522355737","title":"Relmada Therapeutics Inc -on March 24, Enters Exclusive License Agreement With Trigone Pharma - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2522355737","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522355737?lang=en_us&edition=full_marsco","pubTime":"2025-03-27 05:03","pubTimestamp":1743023020,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250326:nFWN3Q90X2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522029545","title":"BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522029545","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522029545?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:34","pubTimestamp":1742902448,"startTime":"0","endTime":"0","summary":"BRIEF-Relmada Therapeutics Licenses Phase 2 Bladder Cancer Candidate, NDV-01, from Trigone Pharma, Ltd.March 25 (Reuters) - Relmada Therapeutics Inc RLMD.O:RELMADA THERAPEUTICS LICENSES PHASE 2 BLADDE","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q804V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2522029843","title":"Relmada- to Pay up to $200 Mln in Development, Regulatory,Sales Milestones Pending Successful Commercialization","url":"https://stock-news.laohu8.com/highlight/detail?id=2522029843","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522029843?lang=en_us&edition=full_marsco","pubTime":"2025-03-25 19:30","pubTimestamp":1742902206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250325:nFWN3Q804V:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","RLMD"],"gpt_icon":0},{"id":"2521714099","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2521714099","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521714099?lang=en_us&edition=full_marsco","pubTime":"2025-03-24 18:00","pubTimestamp":1742810400,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Comp de San Bas                                  4Q       .36       AMC. ·Oklo Inc. Class A                               4Q      (.07)      AMC. ·Core & Main Inc.                                 4Q       .36       BMO. ·McCormick & Co                                 1Q       .64   6:30 AM","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SDST","IKT","WGO","KOD","TEN","KBH","MDAI","CHWY","PDSB","FBIO","PAYS","IOBT","ZURA","WBA","ACRV","CRMD","IVA","DLTR","ABL","GOVX","EDAP","SURG","BEEM","CALC","CDLR","RVPH","AFMD","GRDN","PAYX","MREO","CLSD","UNCY","MKC","ANTX","LPTX","DERM","SKYX","OBIO","SCS","SLRN","WOOF","THRD","BCAB","XFOR","RLMD","CTAS","ALUR","CNXC","MLKN","NUTX"],"gpt_icon":0},{"id":"2521172612","title":"Psychedelic: Exclusive talk with biotech company Clearmind Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2521172612","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521172612?lang=en_us&edition=full_marsco","pubTime":"2025-03-22 22:30","pubTimestamp":1742653811,"startTime":"0","endTime":"0","summary":"In this edition of “Psychedelic”, The Fly conducted an exclusive interview with Mark Haden, vice president of business development at Clearmind Medicine , a psychedelic pharmaceutical biotech company focused on development of therapeutics to solve underserved health problems. Here are some highlights:. Discover stocks' market position with detailed  competitor analyses.“Think of this space as being two overlapping circles, a Venn diagram,” Haden said. “There are addiction treatments, like counseling, Alcoholics Anonymous and some pharmaceutical interventions like Antabuse, naltrexone and acamprosate. I ran an addictions treatment program for 28 years and I can assure you that there is relatively low efficacy, the dropout rate is high, and the treatments tend to be very long-term. That’s the first circle.”“You can take MEAI if you are addicted to alcohol and you don’t want to stop,” Haden said. “You can add MEAI to your alcohol and we believe it will result in people drinking less. It c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-exclusive-talk-biotech-company-143011967.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SEEL","OPTHF","PHRRF","BETRF","QNTM","MYCOF","IXHL","SPRC","BK4547","FLHLF","MDXXF","BK4139","BK4539","ATAI","RLMD","PBM","CMPS","NUMIF","BK4007","MIRA","RVVTF","GHRS","CMND","ALID","AGNPF","SILO","KTTA","ENTBF","DRUG","CYBN","PSYGF","MNMD","SNPX","BK4168","NRXP","BK4202"],"gpt_icon":0},{"id":"2520439968","title":"Calendar of U.S. Earnings Expected in the Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2520439968","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520439968?lang=en_us&edition=full_marsco","pubTime":"2025-03-20 18:00","pubTimestamp":1742464800,"startTime":"0","endTime":"0","summary":"Major companies tentatively scheduled to report quarterly earnings in the week ahead, with earnings estimates provided by FactSet Research Systems Inc.·Amprius Tech Inc                                4Q      (.11)  4:05 PM. ·Lands' End Inc.                                   4Q       .57   6:45 AM. ·Lennar Corp Class A                              1Q      1.70       AMC","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WOR","LPTX","SPRY","OUST","SOWG","BRAG","GDEV","COYA","CMC","BRNS","THRD","SKYE","TELA","CURV","CELC","RLMD","TITN","BBNX","MLKN","LEN","PAYX","BLRX","ACRV","ALUR","KLC","NKTX","FLUX","DERM","LVTX","CBUS","MNSO","SLS","TH","FBRX","CDLR","JEF","MBRX","ASO","NKE","MREO","DRI","JKS","IFRX","MGNX","RUM","SBS","BCAB","PL"],"gpt_icon":1},{"id":"2519330968","title":"Relmada Therapeutics Inc  expected to post a loss of 70 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2519330968","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519330968?lang=en_us&edition=full_marsco","pubTime":"2025-03-15 04:56","pubTimestamp":1741985765,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics Inc  expected to post a loss of70cents a share - Earnings Preview Relmada Therapeutics Inc RLMD.OQ RLMD.O is expected to show no change in quarterly revenue when it reports  resul","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250314:nL8N3PX26S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RLMD"],"gpt_icon":0},{"id":"2519638156","title":"Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2519638156","media":"TipRanks","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519638156?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 23:40","pubTimestamp":1741966809,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on a dosing initiation, a development expansion and a distribution agreement.Discover stocks' market position with detailed  competitor analyses.MIRA EXPANDS KETAMIR-2 DEVELOPMENT WITH TOPICAL: On Thursday, MIRA Pharmaceuticals  announced the formulation of Ketamir-2 into a topical treatment for localized neuropathic and inflammatory pain. This expands the company’s pain management portfolio beyond its ongoing Ketamir-2 oral treatment for neuropathic pain, offering a novel, targeted approach for localized pain relief. The topical treatment of Ketamir-2 is designed for slow release, delivering targeted pain relief directly at the application site while minimizing systemic exposure and side effects.“The development of both an oral and topical formulation of Ketamir-2 significantly expands our pipeline and enhances the value proposition of MIRA,” stated Erez Aminov, CEO . “By adv","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/psychedelic-atai-reports-dosing-first-154009720.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ENVB","RLMD","MYCOF","BK4202","SILO","NUMIF","SNPX","DRUG","FLHLF","MNMD","BK4168","ATAI","RVVTF","KTTA","BK4539","BETRF","AGNPF","CMND","PBM","NRXP","CYBN","CMPS","SPRC","ENTBF","QNTM","SEEL","BK4139","PSYGF","BK4007","GHRS","IXHL","MDXXF","PHRRF","ALID","OPTHF","BK4547","MIRA"],"gpt_icon":0},{"id":"2509760718","title":"Asarina Pharma Ab (Publ) - Signs Asset Purchase Agreement With Relmada Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2509760718","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509760718?lang=en_us&edition=full_marsco","pubTime":"2025-02-07 15:30","pubTimestamp":1738913420,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250207:nFWN3OY0K8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RLMD","BK4007"],"gpt_icon":0},{"id":"2509278640","title":"Relmada Therapeutics acquires Sepranolone from Asarina Pharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2509278640","media":"TIPRANKS","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509278640?lang=en_us&edition=full_marsco","pubTime":"2025-02-06 20:45","pubTimestamp":1738845925,"startTime":"0","endTime":"0","summary":"Relmada Therapeutics (RLMD) announced the acquisition of Sepranolone, a Phase 2b ready neurosteroid, from Asarina Pharma AB, being developed for th...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-acquires-sepranolone-from-asarina-pharma?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/relmada-therapeutics-acquires-sepranolone-from-asarina-pharma?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","RLMD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.relmada.com","stockEarnings":[{"period":"1week","weight":0.0133},{"period":"1month","weight":-0.0209},{"period":"3month","weight":-0.2247},{"period":"6month","weight":-0.9197},{"period":"1year","weight":-0.9381},{"period":"ytd","weight":-0.4427}],"compareEarnings":[{"period":"1week","weight":0.0035},{"period":"1month","weight":-0.0617},{"period":"3month","weight":-0.1191},{"period":"6month","weight":-0.0995},{"period":"1year","weight":0.0517},{"period":"ytd","weight":-0.1018}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":-0.006257},{"month":2,"riseRate":0.571429,"avgChangeRate":0.05562},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.024636},{"month":4,"riseRate":0.714286,"avgChangeRate":0.035628},{"month":5,"riseRate":0.428571,"avgChangeRate":0.009291},{"month":6,"riseRate":0.142857,"avgChangeRate":-0.112899},{"month":7,"riseRate":0.714286,"avgChangeRate":0.090315},{"month":8,"riseRate":0.428571,"avgChangeRate":0.000624},{"month":9,"riseRate":0.857143,"avgChangeRate":0.103955},{"month":10,"riseRate":0.428571,"avgChangeRate":0.103531},{"month":11,"riseRate":0.285714,"avgChangeRate":-0.078877},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.004877}],"exchange":"NASDAQ","name":"Relmada Therapeutics, Inc.","nameEN":"Relmada Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Relmada Therapeutics, Inc.(RLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Relmada Therapeutics, Inc.,RLMD,Relmada Therapeutics, Inc.股票,Relmada Therapeutics, Inc.股票老虎,Relmada Therapeutics, Inc.股票老虎国际,Relmada Therapeutics, Inc.行情,Relmada Therapeutics, Inc.股票行情,Relmada Therapeutics, Inc.股价,Relmada Therapeutics, Inc.股市,Relmada Therapeutics, Inc.股票价格,Relmada Therapeutics, Inc.股票交易,Relmada Therapeutics, Inc.股票购买,Relmada Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Relmada Therapeutics, Inc.(RLMD),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Relmada Therapeutics, Inc.(RLMD) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction